Turn Therapeutics reports FY2025 net loss of $3.2M; secures up to $25M venture debt

Turn Therapeutics Inc.

2026-Q1 EPS reported -$0.03

Cash and equivalents $5.08M as of Dec 31, 2025, excludes $7M initial tranche from Avenue Capital facility.
Net loss $3.19M vs $1.77M in 2024; G&A rose to $5.5M from $1.5M on public listing costs.
Phase 2 trial of GX-03 for atopic dermatitis on track; topline results expected mid-2026.
Appointed former CDC Director Dr. Robert Redfield and Martin Dewhurst (ex-McKinsey) to leadership/board.
Entered global license, supply, and distribution agreement with Medline; revenue expected to begin late 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Turn Therapeutics Inc. reported the year ended December 31, 2025 results: net income NET LOSS $ (3,194,080 ), EPS Basic and diluted net loss per common share $ (0.12 ).

Period: the year ended December 31, 2025
Net income: NET LOSS $ (3,194,080 )
EPS: Basic and diluted net loss per common share $ (0.12 )
Result: reported results

Exact text from the filing

liability 380,442 - Amortization of deferred offering cost (496,948 ) - Interest income 29,583 28,709 Other income 176,520 - Total other income 2,664,568 28,709 NET LOSS $ (3,194,080 ) $ (1,768,415 ) Basic and diluted net loss per common share $ (0.12 ) $ (0.07 ) Weighted-average common shares outstanding, basic and diluted 27,716,045 26,643,432 Turn

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Turn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-037470

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.